Navigation Links
DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Date:5/16/2013

y in China is to develop new clinical and non-clinical data in collaboration with leading cancer researchers to demonstrate the utility of VAL-083 in the treatment of CML and lung cancer, particularly for patients who do not respond to, or cannot access, modern treatments such as tyrosine kinase inhibitors.  We believe these new data, if favorable, will allow the repositioning of VAL-083 in the China market, and eventually global markets, for the treatment of hematologic cancers and solid tumors.  We anticipate seeking a marketing partner for VAL-083 in China that can deliver royalty revenue from that market in the near-term.

During the quarter ended March 31, 2013 we completed a private placement and reverse take-over transaction resulting in the public listing of our shares.  Proceeds from the offering, net of direct and associated expenses, were $8.58 million, and our stock is now trading on the OTCQB under the symbol "DMPI." 

As at March 31, 2013 we have cash and equivalents of $7.53 million.  Based on our current operating budget, these funds provide us with working capital to fund our drug development and corporate activities for at least 24 months.

Details of our financing transaction and our quarterly financials can be found via the SEC Filings section of our website at:  http://www.delmarpharma.com/investors/sec_filings/.

In addition, we will be hosting a free, virtual company presentation on June 6th at 10:45 am EDT.  This will be a live, interactive online event where attendees can ask questions in real-time.  If you cannot join at this time, an on-demand archive will be available for 90 days.  We recommend pre-registering online at www.Retailinvestorconferences.com to sav
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
(Date:10/31/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights Conference ... ET / 8:30 a.m. PTWhere: , www.isispharm.com ... onto our website listed above. If you are unable ... the webcast will be available for a limited time ...
(Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
... many, clinical studies are few, NEW YORK, ... revealed that a limited amount of clinical research ... anti-aging,products. The study is published in the July/August ... peer-reviewed journal of the,American Society for Aesthetic Plastic ...
... (Amex: IMM ) commented today on a ... group of researchers at the National Cancer Institute,on ... enzyme involved in the DNA,repair process (see Note ... proprietary, orally bioavailable prodrug, pafuramidine. Of,interest is furamidine,s ...
Cached Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3
(Date:10/30/2014)... treatments for injuries and damage to the joints, including ... is a hard material that caps the ends of ... biomedical engineers, exploring ways to toughen up engineered cartilage ... new developments this week in the journal Proceedings ... problem with engineered tissue is that the mechanical properties ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
(Date:10/30/2014)... Portland, OR (PRWEB) October 30, 2014 ... law firm Hodgkinson Street LLC announces new branding ... Hodgkinson Street Mepham . After David Mepham’s promotion ... revitalizes their brand and website to include Mepham’s name ... leading medical malpractice and mediation firm, the decision to ...
(Date:10/30/2014)... Tara Haelle ... News) -- More than 100 genes have been identified ... studies report. And researchers say they are on ... that may contribute to the disorder. Autism spectrum ... communication and social difficulties and repetitive behaviors. An estimated ...
(Date:10/30/2014)... 30, 2014 Global prebiotics market is ... to a new study by Grand View Research, Inc. ... for sugar and fat free products owing to increased ... for prebiotics over the forecast period. , View full ... Food & beverage was the largest application segment with ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... Demonstrate Deepening Relationship , Between Edwards and Primary Sponsor ... off its first year as primary sponsor of Carl ... big way with the launch of its latest television ... to air during the national broadcast of the Feb. ...
... Prevent Preterm BirthWHITE PLAINS, N.Y., Feb. 11 ... may cause preterm labor in some women, investigate ... contractions and an early birth, and look at ... environmental risk factors for prematurity.The work of seven ...
... and St George,s, University of London measured recent exposure to ... British Regional Heart Study by measuring the levels of cotinine ... time points 20 years apart. A blood cotinine level above ... of a heart attack (2), and other studies have suggested ...
... Results of a recent study conducted by researchers ... show that cognitive functioning abilities drop as average blood ... , The study appears in this month,s issue of ... Diabetes (MIND) study, a sub-study of the Action to ...
... French . , Montreal, February 11th, 2009 ... the nutrients the tumours receive through the blood. The team ... McGill University Health Centre (MUHC) at the Montreal Children,s Hospital, ... a new mechanism that tumours use to stimulate the growth ...
... world,s first phase one FDA-approved clinical trial using adult ... conducted by a team of University of Louisville ... with advanced heart disease who already are undergoing bypass ... trial, which uses adult stem cells taken from the ...
Cached Medicine News:Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 2Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 3Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 4Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 2Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: